Vittoria Biotherapeutics Inc. has received FDA clearance of its IND application to initiate a first-in-human phase I trial with VIPER-101, a gene-edited, autologous, chimeric antigen receptor (CAR) T-cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma.
Chimeric Therapeutics Ltd. has received FDA clearance of its IND application for CHM-2101, a first-in-class CDH17 chimeric antigen receptor (CAR) T cell therapy for gastrointestinal (GI) cancers.
Caribou Biosciences Inc. has received FDA clearance of its IND application for CB-012, an allogeneic anti-C-type lectin-like molecule-1 (anti-CLL-1) chimeric antigen receptor (CAR) T-cell therapy. CLL-1 is highly expressed on acute myeloid leukemia (AML) cells and leukemic stem cells, but it is not expressed on hematopoietic stem cells.
Cimeio Therapeutics Inc. has entered into a preclinical research collaboration with a researcher at the University of Pennsylvania (Penn) to research and evaluate a novel universal immunotherapy with potential to treat multiple blood and bone marrow cancers.
Sparx Group has formed a strategic alliance with Arovella Therapeutics Ltd. for the development of a CLDN18.2-chimeric antigen receptor (CAR)-invariant natural killer T (iNKT) cell therapy.
Glycotope GmbH and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (Glycotargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.
A new method of CAR T-cell immunotherapy developed by researchers at the University of Pennsylvania Perelman School of Medicine could serve as a treatment for most blood cancers. Until now, CAR T-based immunotherapy for hematological malignancies has targeted the antigens CD19 for B cells, CD7 for T cells, BCMA for myeloma, and CD33 for AML.
Leucid Bio Ltd. has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to commence a phase I/II trial of LEU-011 for the treatment of adults with relapsed or refractory solid tumors.
Verismo Therapeutics Inc. has entered into a licensing agreement with the University of Pennsylvania for worldwide exclusive rights for two newly discovered anti-CD19 binders, the result of a sponsored research agreement between the two parties.
Cytomed Therapeutics Ltd. has signed a memorandum of understanding (MOU) with Hangzhou CNK Therapeutics Co. Ltd. allowing Cytomed to utilize CNK's Piggybac technology to permanently graft the chimeric antigen receptor (CAR) gene into its γδ T cells via a non-viral gene editing method.
RSS
